Inmode Ltd
NASDAQ:INMD
Decide at what price you'd be comfortable buying and we'll help you stay ready.
|
Johnson & Johnson
NYSE:JNJ
|
US |
|
Berkshire Hathaway Inc
NYSE:BRK.A
|
US |
|
Bank of America Corp
NYSE:BAC
|
US |
|
Mastercard Inc
NYSE:MA
|
US |
|
UnitedHealth Group Inc
NYSE:UNH
|
US |
|
Exxon Mobil Corp
NYSE:XOM
|
US |
|
Pfizer Inc
NYSE:PFE
|
US |
|
Nike Inc
NYSE:NKE
|
US |
|
Visa Inc
NYSE:V
|
US |
|
Alibaba Group Holding Ltd
NYSE:BABA
|
CN |
|
JPMorgan Chase & Co
NYSE:JPM
|
US |
|
Coca-Cola Co
NYSE:KO
|
US |
|
Verizon Communications Inc
NYSE:VZ
|
US |
|
Chevron Corp
NYSE:CVX
|
US |
|
Walt Disney Co
NYSE:DIS
|
US |
|
PayPal Holdings Inc
NASDAQ:PYPL
|
US |
P/OCF
Price to Operating Cash Flow (P/OCF) ratio compares a company`s market value to the cash it generates from its core operations.
Price to Operating Cash Flow (P/OCF) ratio compares a company`s market value to the cash it generates from its core operations.
Valuation Scenarios
If P/OCF returns to its 3-Year Average (10), the stock would be worth $13.4 (7% downside from current price).
| Scenario | P/OCF Value | Implied Price | Upside/Downside |
|---|---|---|---|
| Current Multiple | 10.7 | $14.37 |
0%
|
| 3-Year Average | 10 | $13.4 |
-7%
|
| 5-Year Average | 11.8 | $15.82 |
+10%
|
| Industry Average | 11.1 | $14.92 |
+4%
|
| Country Average | 14.8 | $19.89 |
+38%
|
Forward P/OCF
Today’s price vs future operating cash flow
Peer Comparison
| Market Cap | P/OCF | P/E | ||||
|---|---|---|---|---|---|---|
| IL |
|
Inmode Ltd
NASDAQ:INMD
|
912.4m USD | 10.7 | 9.7 | |
| US |
|
Intuitive Surgical Inc
NASDAQ:ISRG
|
171.2B USD | 55.2 | 58.6 | |
| US |
|
Abbott Laboratories
NYSE:ABT
|
158.3B USD | 16.8 | 25.6 | |
| US |
|
Stryker Corp
NYSE:SYK
|
125.3B USD | 25 | 38.8 | |
| IE |
|
Medtronic PLC
NYSE:MDT
|
106.9B USD | 14.6 | 23.1 | |
| US |
|
Boston Scientific Corp
NYSE:BSX
|
92B USD | 19.7 | 25.1 | |
| US |
|
Edwards Lifesciences Corp
NYSE:EW
|
48.9B USD | 30.8 | 44.8 | |
| DE |
|
Siemens Healthineers AG
XETRA:SHL
|
40.1B EUR | 13.2 | 19 | |
| US |
|
IDEXX Laboratories Inc
NASDAQ:IDXX
|
45.1B USD | 38.8 | 43.3 | |
| US |
|
Becton Dickinson and Co
NYSE:BDX
|
43.3B USD | 12.6 | 24.4 | |
| US |
|
Resmed Inc
NYSE:RMD
|
32B USD | 17 | 21.9 |
Market Distribution
| Min | 0 |
| 30th Percentile | 8.8 |
| Median | 14.8 |
| 70th Percentile | 26 |
| Max | 3 711.8 |
Other Multiples
Inmode Ltd
Glance View
InMode Ltd., founded in 2008, has emerged as a dynamic player in the field of minimally invasive aesthetic medical treatments. Born during a period where the health and beauty sectors were experiencing rapid technological innovation, the company quickly carved a niche for itself by addressing a clear market need: the rising demand for non-surgical procedures. At its heart, InMode merges the precision of medical technology with the principles of aesthetic enhancement. Its primary offerings revolve around radio-frequency-based devices that healthcare providers use to achieve results that traditionally required more invasive techniques. This includes skin tightening, fat reduction, and body contouring solutions, all tailored to meet the growing consumer appetite for treatments that carry less downtime and risk compared to conventional surgery. The company monetizes its expertise by manufacturing and selling these state-of-the-art devices to a diverse group of users, ranging from dermatologists and plastic surgeons to aesthetic practices. InMode's revenue streams are bolstered by not only the direct sale of these devices but also by ongoing client relationships through service agreements and consumable products that are essential for their machine operation. It is a model that ensures continuous engagement with their clients, providing both stability and growth in revenue. By focusing on innovation and efficacy, InMode has successfully captured a significant share of the aesthetic medical market, embodying a business strategy that combines cutting-edge technology with practical solutions to consumer needs.